Open AccessComparison of HER‐2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management
Author(s) -
Guarneri Valentina,
Giovannelli Simona,
Ficarra Guido,
Bettelli Stefania,
Maiorana Antonino,
Piacentini Federico,
Barbieri Elena,
Dieci Maria Vittoria,
D'Amico Roberto,
Jovic Gordana,
Conte PierFranco
Publication year - 2008
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2008-0048
Subject(s) - medicine , immunohistochemistry , breast cancer , cancer , primary tumor , oncology , fluorescence in situ hybridization , pathology , metastasis , biochemistry , chemistry , chromosome , gene
. The assessment of hormone receptors (HRs) and human epidermal growth factor receptor (HER)‐2 is necessary to select patients who are candidates for hormonal and anti–HER‐2 therapy. The evaluation of these parameters is generally carried out in primary tumors and it is not clear if reassessment in metastatic lesions might have an impact on patient management. The primary aim of this analysis was to compare HER‐2 and HR status in primary tumors versus metastatic sites in breast cancer patients. Patients and Methods. Seventy‐five patients with available samples from primary tumors and paired metastases were included. HER‐2 status was evaluated by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH); HR status was assessed by IHC. Results. Nineteen percent of primary tumors were HER‐2 positive; 77% were HR positive. Sites of biopsied or resected metastases were: locoregional soft tissues ( n = 30), liver ( n = 20), central nervous system ( n = 5), bone ( n = 5), pleura ( n = 4), distant soft tissues ( n = 3), abdomen (stomach, colon, peritoneum) ( n = 3), bronchus ( n = 3), and bone marrow ( n = 2). For paired metastases, the HER‐2 status was unchanged in 84% of cases; two patients changed from positive to negative, while 10 patients converted from negative to positive (agreement, 84%; κ = 0.5681). A change in HR status was observed in 16 cases (21%): nine cases from positive to negative and seven cases from negative to positive (agreement, 78.7%; κ = 0.4158). Conclusions. Further studies are necessary to better define the level of discordance in HER‐2 or HR status between primary tumors and paired metastases. However, a biopsy of metastatic disease can be recommended, if feasible with minimal invasiveness, because treatment options might change for a significant proportion of patients.